Can the risk of antibody formation be reduced?
• Repeated, high dose injections are far more likely to result in antibody formation than are less frequently repeated, low dose injections. • Physicians should, therefore, use the smallest amount of BTX-A necessary to achieve therapeutic benefit and extend the interval between treatment sessions as long as possible. • Antibody assays can be obtained through Northview Pacific Laboratories, 2800 7th Street, Berkeley, CA. 94710, (510) 548-8440. • Can BTX-A booster injections be given without causing resistance? (Possibly) • When the amount injected totals the maximum of 400 units, due to the risk of producing resistance, further injections should not be given before three months after the last BTX-A treatment. • The interval between treatments to improve clinical objectives should be extended as long as possible. • The smallest amount of BTX-A necessary to achieve the desired effect is suggested. • Frequent injections do increase the chances of antibody formation.
Related Questions
- Are all combined hormonal contraceptives at risk for reduced effectiveness if a patient is being treated for hepatitis?
- How can the risk of chronic liver disease be reduced among people chronically infected with hepatitis B?
- How important are business impact analysis and risk assessment to the formation of a BC/DR plan?
